Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Using targeted therapies for inflammatory dermatoses.

Sobell JM.

Semin Cutan Med Surg. 2018 Sep;37(3):133. doi: 10.12788/j.sder.2018.050. No abstract available.

PMID:
30215628
2.

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.

Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA.

Am J Clin Dermatol. 2018 Jun;19(3):437-447. doi: 10.1007/s40257-017-0341-6.

3.

Update on TNF Inhibitors in Dermatology.

Sobell JM.

Semin Cutan Med Surg. 2016 Jun;35(6 Suppl):S104-6. doi: 10.12788/j.sder.2016.033.

PMID:
27537073
4.

Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.

Sobell JM, Foley P, Toth D, Mrowietz U, Girolomoni G, Goncalves J, Day RM, Chen R, Yosipovitch G.

Acta Derm Venereol. 2016 May;96(4):514-20. doi: 10.2340/00015555-2360.

5.

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.

Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, Teixeira HD, Jemec GB.

J Eur Acad Dermatol Venereol. 2016 Jun;30(6):989-94. doi: 10.1111/jdv.13216. Epub 2015 Jul 22.

6.

Therapeutic development in psoriasis.

Sobell JM, Leonardi CL.

Semin Cutan Med Surg. 2014 Jun;33(4 Suppl):S69-72. doi: 10.12788/j.sder.0098. Review.

PMID:
25268599
7.

The role of TNF inhibitors in psoriatic disease.

Mandell BF, Sobell JM.

Semin Cutan Med Surg. 2014 Jun;33(4 Suppl):S64-8. doi: 10.12788/j.sder.0097. Review.

PMID:
25268598
8.

Introduction. Dermatitis.

Sikora BC, Sobell JM.

Semin Cutan Med Surg. 2013 Sep;32(3):131. No abstract available.

PMID:
24175399
9.

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.

Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M.

Dermatol Ther (Heidelb). 2012 Dec;2(1):2. doi: 10.1007/s13555-012-0002-x. Epub 2012 Mar 30.

10.

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1.

Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M.

Dermatol Ther (Heidelb). 2012 Dec;2(1):1. doi: 10.1007/s13555-012-0001-y. Epub 2012 Mar 17.

11.

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.

Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM.

Br J Dermatol. 2012 Dec;167(6):1374-81. doi: 10.1111/bjd.12000. Epub 2012 Nov 2.

PMID:
22897348
12.

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.

Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, Gu Y, Okun MM.

Br J Dermatol. 2012 Sep;167(3):658-67. doi: 10.1111/j.1365-2133.2012.11041.x. Epub 2012 Aug 20.

PMID:
22564148
13.

A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach.

Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M.

J Am Acad Dermatol. 2009 Jul;61(1 Suppl 1):S1-S46. doi: 10.1016/j.jaad.2009.03.017.

PMID:
19527820
14.

Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agents.

Sobell JM, Kalb RE, Weinberg JM.

J Drugs Dermatol. 2009 Mar;8(3):230-8. Review.

PMID:
19271369
15.

Patient fatalities potentially associated with efalizumab use.

Sobell JM, Weinberg JM.

J Drugs Dermatol. 2009 Mar;8(3):215. No abstract available.

PMID:
19271366
16.

Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents.

Sobell JM, Kalb RE, Weinberg JM.

J Drugs Dermatol. 2009 Feb;8(2):147-54. Review.

PMID:
19213230
17.

Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial.

Kimball AB, Jackson JM, Sobell JM, Boh EE, Grekin S, Pharmd EB, Woolley JM, Xia HA, Chiou CF, Stevens SR.

J Drugs Dermatol. 2007 Mar;6(3):299-306.

PMID:
17373192
18.

Successful treatment of a widespread inflammatory verrucous epidermal nevus with etanercept.

Bogle MA, Sobell JM, Dover JS.

Arch Dermatol. 2006 Mar;142(3):401-2. No abstract available.

PMID:
16549730
19.

Overview of biologic agents in medicine and dermatology.

Sobell JM.

Semin Cutan Med Surg. 2005 Mar;24(1):2-9. Review.

PMID:
15900793
20.

Systemic therapies for psoriasis: understanding current and newly emerging therapies.

Sobell JM, Hallas SJ.

Semin Cutan Med Surg. 2003 Sep;22(3):187-95. Review.

PMID:
14649586

Supplemental Content

Loading ...
Support Center